STUDresearch · Peptide
Melanotan II
Also known as
MT2 · MT-II · Melanotan 2 · Melanotan-II · MT-2 · MT II · Barbie drug · tan jab · Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 · Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-α-MSH4-10-NH2
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Systemic
SubQ / Nasal
Tanning & melanocortin
Systemic melanocortin agonist discussed for pigmentation, appetite and arousal; community products are unapproved injections or nasal sprays.
What people say
Melanotan II is a cyclic α-MSH analog and systemic melanocortin agonist studied in very small 1990s–2000s human pilots. It is not approved for cosmetic tanning, and illegal internet vials have shown content mismatch.
Doses people talk about
These are separate observational and clinical contexts, not a progression. UV, product identity, population and endpoints differ, and reconstitution volume was not used to infer any dose.
How it may feel
Acute clinical effects included nausea, yawning/stretching and 1–5-hour intermittent erections. Community pigmentation reports ranged from strong color by week three to little tan with increasing freckles, with changing UV and unverified products.
Observed three-week community course100 mcg daily, then 250 mcg every 2 days, then 250 mcg weekly
Same author reported three 12-minute tanning sessions before the photo, marked color and small arm freckles.
Observed adverse community course250 mcg twice in week 1, then 100 mcg daily for 3 days
Same author stopped for one week after many freckles, then reported little tan and more freckles; nausea followed the 250 mcg amounts.
Dorr Phase I exposure0.01–0.03 mg/kg SC
Three healthy men started at 0.01 mg/kg and some escalated in 0.005 mg/kg steps during alternating weekday dosing.
Organic ED crossover exposure0.025 mg/kg SC
Ten men received active drug twice in a placebo-controlled crossover with six-hour erection monitoring.
Half-life & effect duration
- Half-life in the body
- IV · rat estimatesTens of minutes to about 1 hour
- Human parent peptideNo settled estimate
- Felt duration people report
- Intermittent erections · small studyAbout 1–5 hours
- Nausea · community reportsOften strongest in the first 30–90+ minutes
- Pigment accountMarked color by week 3 after exposure changes
- Other accountFreckles with little tan
Cycles people discuss
Community accounts describe daily or every-other-day loading followed by sparse maintenance, usually seasonally. Those are observed habits, not a validated cosmetic protocol. Preserved notes list changing lesions or intolerable adverse effects as reasons to stop; the inspected reports do not establish how common any trigger is.
Timing
Community tanning use typically loads daily or every other day for one to three weeks, then shifts to sparse weekly or biweekly maintenance. The inspected acute trial context used intermittent dosing; bedtime use and a 30–90-minute nausea window were not established.
Stacks
UV exposure varied across inspected community reports and confounds pigmentation attribution; it is not a reviewed timed stack or validated exposure schedule.
Access talk
Not an approved tanning drug: Gray-market vials and nasal ‘tanning sprays’ are the 2025–26 buy path — not a pharmacy bottle.
Labs people mention
Skin > labs: 2025–26 careful threads watch moles/freckles with a derm, not a ‘tan panel.’
Watch for
Moles / freckles / naevi: Darkening, enlargement, eruptive new moles/freckles, and rapid lesion change are among the most serious dermatologic concerns in case series; changing lesions need professional evaluation.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A human parent-plasma half-life for Melanotan II was not established in the reviewed sources.
The Dorr and Wessells human studies report SC amounts, observed effects and adverse events, but the reviewed abstracts do not report a parent-plasma elimination estimate.
Do not import rat IV kinetics, melanotan-I PK or community onset estimates into MT-II human half-life.
- Evaluation of melanotan-II in a pilot Phase I clinical study (opens in a new tab)Three healthy men received alternating MT-II or saline weekday SC injections over two weeks, starting at 0.01 mg/kg with 0.005 mg/kg escalation; erections lasted intermittently 1–5 hours and 0.03 mg/kg caused somnolence/fatigue in one participant.Tiny 1990s male pilot; it does not establish long-term cosmetic safety, parent PK, or gray-market product equivalence. PubMed abstract content was reviewed.
- Melanotan II in men with organic erectile dysfunction (opens in a new tab)Double-blind placebo-controlled crossover in ten men; 0.025 mg/kg SC was given twice, erections were monitored for six hours, and nausea plus yawning/stretching occurred more often with MT-II.Small male ED study focused on erectogenic response, not cosmetic tanning or plasma pharmacokinetics. PubMed abstract content was reviewed.
Felt duration people report
A three-person Phase I pilot recorded intermittent spontaneous erections for 1–5 hours after SC MT-II dosing.
Yawning and stretching appeared with erection onset; the duration varied with dose. A separate ten-man ED crossover monitored response over six hours.
Very small male studies with sexual-function endpoints; this does not establish tanning onset, general subjective duration or gray-market-product effects.
- Evaluation of melanotan-II in a pilot Phase I clinical study (opens in a new tab)Three healthy men received alternating MT-II or saline weekday SC injections over two weeks, starting at 0.01 mg/kg with 0.005 mg/kg escalation; erections lasted intermittently 1–5 hours and 0.03 mg/kg caused somnolence/fatigue in one participant.Tiny 1990s male pilot; it does not establish long-term cosmetic safety, parent PK, or gray-market product equivalence. PubMed abstract content was reviewed.
- Melanotan II in men with organic erectile dysfunction (opens in a new tab)Double-blind placebo-controlled crossover in ten men; 0.025 mg/kg SC was given twice, erections were monitored for six hours, and nausea plus yawning/stretching occurred more often with MT-II.Small male ED study focused on erectogenic response, not cosmetic tanning or plasma pharmacokinetics. PubMed abstract content was reviewed.
Felt duration people report
Community pigmentation onset varied and cannot be assigned one reliable duration.
One author described marked color by week three after changing 100-to-250 mcg exposure and three tanning sessions; another described freckles with little tan after interrupted 250-to-100 mcg use.
Anonymous reports, unverified products, different skin types and changing UV prevent causal timing inference.
- Reddit r/Melanotan2 — 3 weeks on MT2 (opens in a new tab)Same author reported 100 mcg daily for seven days, 250 mcg every two days in week two, then 250 mcg weekly; three 12-minute tanning sessions preceded the photo and small arm freckles were reported.Anonymous self-report with unverified product, uncontrolled UV and image conditions, and no independent outcome measurement.
- Reddit r/Melanotan2 — Change up of doseage advice (opens in a new tab)Same author reported two 250 mcg doses in week one, a one-week stop after many freckles, then 100 mcg daily for three days with little tan and more freckles; nausea followed 250 mcg.Anonymous self-report with unverified product, changing UV exposure and no dermatologic assessment.
- Reddit r/Melanotan2 — MT2 2 weeks of 250mcg nightly (opens in a new tab)Author reported 250 mcg nightly for two weeks with 30–60 minutes of sun most days, then 250 mcg once or twice weekly; stomach upset and flushing were limited to the first days.Anonymous self-report with unverified product and substantial concurrent UV; no controlled comparator.
Other context in this card
- Identification of melanotan II products sold illegally online (opens in a new tab)LC-UV-MS/MS testing found 4.32–8.84 mg total MT-II in vials advertised as 10 mg.Small market sample from a particular time and vendors; does not characterize every present-day product.
What people say
- Skin darkening: Progressive eumelanin-type bronze over days–weeks; freckles and moles often darken first and can look “spotty” before a smoother base. forumtrial
- UV-assisted efficiency: Community claim is deeper color with less sunbed/outdoor time than UV alone; habits, baseline phototype, and product fill confound every log. forum
- Libido / desire: Increased sexual interest is a frequently logged effect; Wessells summaries reported increased desire after a majority of MT-II doses vs placebo in ED research cohorts. trialforum
- Appetite reduction: MC4R-linked lower hunger / easier calorie control appears often in logs and animal melanocortin work; human cosmetic-use weight effect is anecdotal and confounded. forumanimal
- Even bronze narrative: Some report relatively uniform body color once base builds; others get patchy freckle/mole accentuation, uneven face vs body, or “leopard” freckling that looks uneven. forum
- Hair / body hair: Darkening of body hair, existing freckles, and sometimes facial hair is commonly reported and not always wanted. forum
- Nail / soft-tissue pigment talk: Consumer summaries list dark nail lines and uneven pigment as possible cosmetic downsides alongside freckle/mole change. forum
- Maintenance hold: After load, color often holds weeks on sparse shots plus light UV; fades over weeks off-product while freckle/mole darkening may lag. anecdote
- vs Melanotan I (community): Stronger tan per lower cumulative mcg for many, cheaper per “result” talk, but more nausea, libido, and appetite effects because of broader receptor hit; MT-I framed as more pigment-selective and needing more peptide. forum
- vs PT-141: Dual tan + arousal profile on MT-II; PT-141 (bremelanotide) is framed as libido-focused with minimal intentional tanning and is the FDA-approved Vyleesi path for HSDD in premenopausal women — not a tanning drug. trialforum
- Tan-load vs libido (2025–26 split): r/Melanotan2 still argues two jobs. Daily/EOD loading is for color; sexual sides can show on dose one. Logs that only wanted the bedroom effect often stop the load when face/freckles outrun the tan, then talk PT-141 instead of more MT-II. forum
- Women’s discussion: Tanning-first use common; libido upticks and nausea also reported; clinical ED erection data do not map 1:1 to female sexual-function claims. forum
- Cosmetic driver honesty: Primary use is aesthetic/libido; photoprotection and “skip sunscreen” claims outrun solid evidence — MT-II is not proven UV protection or a melanoma-risk reducer. forumtrial
- Low-dose clinical pigment signal: Dorr et al. pilot (n=3 men): measurable face/upper-body/buttock darkening after only five low SC doses on alternating days in some volunteers; quantitative reflectance used. trial
- Erections (men): Spontaneous or enhanced erectile response without sexual stimulation in research cohorts; RigiScan-confirmed in psychogenic (e.g., 8 of 10 men in one psychogenic ED pilot) and organic ED work. trial
Doses people talk about
- Community micro / first-test band: ~100–250 mcg first doses (some charts start ~100–200 mcg) to gauge nausea, flushing, and sexual sides before any climb. forum
- Common start-then-load pattern: Days 1–2 or 1–3 at ~250 mcg daily, then climb toward ~500 mcg daily if tolerated — the most repeated “standard protocol” across peptide-education posts. forum
- Common loading band: ~250–500 mcg per SC injection, typically once daily or every other day during load. forum
- Sexual-function community band (off primary tan charts): ~500 mcg–1 mg SC as-needed appears in comparison posts when people discuss arousal without full tanning loads; still gray-market and side-heavy vs PDE5 lore. forum
- Libido-only vs tan-load (2025–26): Tan culture stays hundreds of mcg daily/EOD. Threads taking it ‘for sex, not tanning’ still talk ~0.5–1.5 mg class PRN, which is where nausea, knock-out fatigue, and ‘won’t go down’ notes get louder — not the vacation-tan chart. forum
- Loading duration: Often ~7–14 days at daily/EOD, sometimes extended to ~2–4+ weeks depending on phototype, UV, and tolerance. forum
- Skin-type cumulative lore (forum charts): Fair types (Fitzpatrick I–II) discussed as needing much higher total mg over a season (charts sometimes cite ~20–50 mg cumulative) vs type III–V often claiming visible tan under ~10 mg total — highly individual, UV-dependent, and unverified. forum
- Maintenance band: ~100–500 mcg once or twice weekly (or less) after target color; some hold with light UV and very sparse shots; some charts cite ~250 mcg 1–2×/week or ~500 mcg 2×/week as common “hold” figures. forum
- Evening timing: Bedtime dosing is the dominant nausea-management habit so peak GI sides hit during sleep. forum
- EOD vs daily debate: Some prefer every-other-day load to cut cumulative nausea while still building pigment; others run daily for faster base — both are community patterns, not trial-standardized cosmetic protocols. forum
- UV pairing talk: Guides often pair load with brief controlled UV (commonly discussed ~10–15 or ~10–20 minutes class after tolerance is known) rather than long unprotected burns; pigment does not cancel UV damage. forum
- Nasal spray labeled mcg: Claimed per-spray doses are poorly standardized; community often treats nasal as needing more frequent use and less predictable delivery than vial math. forum
- Nasal vs SC dose talk: Vendor/education posts commonly claim roughly ~30–40% nasal bioavailability vs near-full SC and suggest needing ~2–3× exposure and longer to see color — numbers are secondary summaries, not controlled PK labels for consumer sprays. forum
- Purity / fill risk: Gray-market 10 mg labels have been found underfilled in analytical work (published LC-UV-MS/MS spot-check of illegal internet products: total MT-II per vial ranged ~4.32–8.84 mg while shops claimed 10 mg); labeled mcg ≠ verified peptide. trial
- Extreme single-dose case (not a protocol): Case report of ~6 mg SC internet product with systemic toxicity and rhabdomyolysis — orders of magnitude above typical community tanning mcg. trial
- Framing: Community- and trial-reported research ranges only — not medical advice, not a use protocol, not a prescription. forum
- Clinical weight-based (ED / early pilots): ~0.025 mg/kg SC was the preferred researched single dose in Wessells ED work and the recommended Phase I figure from Dorr (escalation from ~0.01 mg/kg; ~0.03 mg/kg produced more somnolence/fatigue). For an ~80 kg adult that is on the order of ~2 mg — higher than most fixed community tanning mcg charts. trial
- Dorr phase I schedule shape: Alternating-day SC (MT-II or saline), weekday dosing over ~2 weeks in a tiny pilot; starting 0.01 mg/kg with 0.005 mg/kg steps upward in some subjects. trial
- Wessells ED context: Preferred ~0.025 mg/kg SC; manageable sides at that figure in study framing; severe nausea reported in a minority (~12.9% cited in one sexual-function summary at 0.025 mg/kg). trial
How it may feel
- Nausea peak: Often strongest in the first ~30–90+ minutes; first few doses are frequently the worst before some tolerance. forum
- Early adverse community account: Two 250 mcg doses in week one were followed by nausea and many freckles; after a one-week stop, 100 mcg daily for three days brought little tan and more freckles. forum
- Weeks 1–2 community contrast: One author moved from 100 mcg daily to 250 mcg every two days and reported strong color by week three; another used 250 mcg nightly with near-daily sun and described early GI upset and flushing. forum
- Week 3 observed account: One fair-skinned author reported a marked photo change after a 100-to-250 mcg course and three 12-minute tanning sessions, plus small arm freckles. forum
- Fair skin lag: Fitzpatrick I–II threads often describe slower, higher-cumulative needs and more freckle accentuation before a smooth bronze — sometimes 3–4+ weeks of load talk vs 1–2 weeks for darker types. forum
- Maintenance phase: Once-weekly or twice-weekly (or less) plus light UV to hold; color fades over weeks if stopped. forum
- Load vs hold (2025–26): Libido/erection notes often land on day one; a smoother bronze is still a 1–2 week (or slower) load. Face and freckle darkening can jump in week two — a common reason people ‘call the load’ even when they liked the other sides. forum
- Hours after clinical SC dosing: In a three-man pilot, yawning/stretching tracked with intermittent erections lasting 1–5 hours; mild nausea occurred at most dose levels and 0.03 mg/kg caused somnolence/fatigue in one participant. trial
- Sexual acute window: In men, spontaneous erections often cluster roughly 1–5 hours post-dose in clinical descriptions; desire upticks can appear the same day. trial
Around the dose
- UV habit: Brief sun or bed after a known-tolerated dose. Cover-the-face talk is loud when people do not want a darker face than body. forum
- Not a date-night swap for PT-141: Daily load is pigment. As-needed desire is the other melanocortin card. Stacking both is the overlap-risk lore (nausea, BP, more pigment). forum
- After a load: Sparse weekly/biweekly hold if color is the job; stop and switch-to-PT-141 talk if the job was only libido. forum
- Inspected timing context: Acute effects varied across evidence: a three-man SC pilot observed yawning/stretching with intermittent erections for 1–5 hours and mild nausea, while community reports used different schedules. Bedtime use and a 30–90-minute nausea window are not established here. trial
Cycles people discuss
- Classic pattern: Daily or EOD load until target color → sparse weekly/biweekly maintenance — not a steroid-style bulk/cut cycle. forum
- Loading length: Often ~1–3+ weeks; fair skin and low UV stretch the load. forum
- Maintenance length: Continues as long as color hold is desired; many run maintenance only through a season or trip, not endless daily use. forum
- Seasonal use: Pre-vacation, summer, and competition-prep “tan runs” more common than continuous year-round daily use. forum
- Time off triggers: Stop after goal color, intolerable nausea, new/changing moles, or other concerning sides; long-term safety data for chronic gray-market use is thin. forum
- Re-runs: Later-season or next-year reloads common; prior freckle/mole darkening remains a standing caution and may re-accentuate quickly. forum
- No formal PCT culture: Unlike AAS, threads rarely discuss hormonal post-cycle therapy; focus is mole monitoring, UV habits, and fade. forum
- Women’s cycle talk: Same load→maintain pigment pattern dominates; sexual-effect timing is less protocolized than male ED research doses. forum
- Washout talk: Some research-oriented dosing writeups suggest months-long washout or annual-only framing after a ~2-week research load; forum re-runs are often shorter-interval and seasonal. forum
- ED research context: Sexual-function studies used intermittent research doses, not multi-week cosmetic loading schedules. trial
Timing
- Why color outlasts plasma: Melanogenesis continues after the peptide clears; pigment builds over days and holds after dosing slows — users chase cumulative melanocyte signaling, not steady plasma levels. forumtrial
- Acute AE window: Nausea, flushing, yawning/stretching, and sexual effects cluster within hours of a dose (nausea often strongest first 30–90+ minutes). forumtrial
- Frequency logic: Daily/EOD loading is for cumulative pigment signaling — not because the parent peptide has a long depot half-life. forum
- Spacing sides: Because acute autonomic/GI effects front-load after each shot, once-daily (or less) is the usual discussion pattern rather than multiple same-day doses. forum
- Fade timeline: After stop, general bronze often fades over weeks; freckles/moles and mucosal pigment changes may lag general tone. anecdotetrial
- Human parent half-life: Not established by the reviewed MT-II sources; the inspected human pilots reported dosing, effects and adverse events but not a plasma elimination estimate. trial
- Human Tmax: Not established by the reviewed MT-II sources; do not convert community onset reports into measured plasma peak timing. trial
- Animal IV PK: Rat IV work (e.g., ~0.3 mg/kg class studies with HPLC/bioassay) shows rapid biphasic elimination (order of tens of minutes to ~1 hour class) — supports short circulating peptide, not a multi-day depot. animal
- MT-I human PK adjacency (not MT-II label): Published melanotan-I SC human PK showed short absorption and beta-phase half-lives on the order of under ~2 hours and no detectable oral levels — often cited when people argue melanocortin tanning peptides are short-plasma / inject-only. trial
- Erection timing: Clinical descriptions place intermittent spontaneous erections roughly 1–5 hours after dosing, dose-dependent; mean erection latency on the order of ~1–2 hours after SC in sexual-function summaries — not an on-demand 15-minute PDE5 profile. trial
- RigiScan duration notes: Research summaries describe meaningful rigidity windows lasting tens of minutes on monitoring after active doses (study-dependent; not a consumer performance claim). trial
More on what it is
- Why people use it: Faster/deeper tan with less UV than sun alone is the main search driver; secondary interest in libido, spontaneous erections, and appetite drop. forum
- Potency lore: Reviews and forum summaries often claim melanotan analogues are orders of magnitude more potent than endogenous α-MSH; MT-II is discussed as producing pigment at lower cumulative doses than MT-I with more central sides. forumtrial
- What it is: Synthetic cyclic heptapeptide α-MSH analog (lactam-bridged); gray-market tanning peptide nicknamed the “Barbie drug,” not an FDA-approved cosmetic or prescription tanning drug. trial
- Mechanism talk: Non-selective agonist at MC1R (melanogenesis / eumelanin), MC3R/MC4R (appetite, sexual signaling), and MC5R; crosses into central pathways more than the “MT-I is skin-only” forum lore assumes. trial
- Evidence base: Small 1990s–early-2000s human pilots (Dorr phase I tanning/sides; Wessells psychogenic and organic ED/erection studies with RigiScan); no large modern cosmetic tanning RCTs for gray-market products. trial
- Related lineage: Sexual-arousal side effects steered development toward bremelanotide (PT-141 / Vyleesi); afamelanotide (Scenesse implant, formerly Melanotan I path) is the approved photoprotection cousin for erythropoietic protoporphyria — not MT-II. trial
- Not the same as: FDA cosmetic tanning approval, steroids/SARMs, Scenesse implants, Vyleesi label use, DHA/cosmetic spray tan, or setmelanotide (IMCIVREE) rare-obesity MC4R drug. trial
- Structure shorthand: Often written Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 / Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-α-MSH4-10-NH2; superpotent melanotropic activity vs endogenous α-MSH in early in-vitro/clinical framing. trial
- Regulatory framing: Health agencies (FDA, MHRA, TGA, Skin Cancer Foundation warnings, and others) have warned against unlicensed melanotan products sold as injections or nasal sprays; not approved for consumer tanning. trial
Stacks
- UV co-factor (main “stack”): Short controlled sun or tanning-bed UV is treated as the primary amplifier of visible color; common talk is brief exposures (often ~10–20 minutes class in guides) after tolerance is known — not unlimited burning. forum
- MT-II alone for dual goals: Many choose MT-II specifically for tan + libido/appetite in one compound rather than stacking separate agents. forum
- vs / switch Melanotan I: Switch or compare when nausea or sexual sides dominate and user wants more pigment-selective profile (or reverse for stronger central effects / lower total mg). forum
- PT-141 instead (not usually with): For pure desire/arousal without intentional tanning, threads point to PT-141/bremelanotide rather than stacking both melanocortins casually (overlap of nausea, BP, and residual pigment risk). forum
- MT-II vs PT-141 dose culture (comparison posts): PT-141 often discussed as on-demand ~0.5–1.75 mg class (approved Vyleesi is 1.75 mg SC for HSDD); MT-II tanning culture is daily load hundreds of mcg then weekly hold — different goals and schedules. trialforum
- Fat-loss adjacency: Appetite drop leads to concurrent calorie-deficit, GLP-1, or stimulant talk — effects are confounded and not a formal synergy protocol. forum
- Nausea management (non-stack): Evening dose, lower start mcg, hydration, light snack, and patience through first doses dominate over multi-drug anti-nausea stacks in casual logs; clinical pilots noted mild nausea often not needing antiemetics at low research doses. forumtrial
- Skin-tone adjacency mentions: Glutathione or other “tone” products appear in aesthetic forums but are separate mechanisms, not evidence-based MT-II pairs. forum
- 2025–26 switch, not stack: After a tan load, people who still want the bedroom effect without more pigment talk PT-141 — not MT-II + PT-141 together. forum
- Avoid treating as sunscreen stack: Pairing with UV without sun-protection habits is a major risk discourse; darker pigment ≠ proven cancer protection. trial
- Avoid mega-dose “one shot tan” thinking: Case toxicity after multi-mg single injections is cited as a caution against impatient front-loading. trial
Access talk
- Not an approved tanning drug: Gray-market vials and nasal ‘tanning sprays’ are the 2025–26 buy path — not a pharmacy bottle. forumtrial
- April 2026 Category 2 off: Coming off the do-not-compound bucket is not Category 1, not 503A placement, and not FDA approval. trialforum
- Nasal vs vial: Social-sold sprays remain the identity/dose wild card next to lyophilized research vials. forum
- Not on the July 2026 seven: BPC/KPV/TB-500/MOTS-c/Epitalon/Semax/DSIP were the July 23–24 PCAC peptides. Melanotan II was not in that room. trial
- Next PCAC window: FDA has said another committee meeting before the end of February 2027 will discuss Melanotan II with LL-37, GHK-Cu, Dihexa acetate, and PEG-MGF. Advisory, not a product launch. trial
- Why compounding talk is cautious: FDA safety-risk writeups cite immunogenicity/impurity concerns plus published case reports (melanoma discourse, PRES, sympathomimetic toxidrome, priapism). trial
Labs people mention
- Skin > labs: 2025–26 careful threads watch moles/freckles with a derm, not a ‘tan panel.’ forum
- BP chatter: Autonomic/pressor notes show up; this is not a hormone peptide people titrate off IGF-1 or testosterone. forum
- No MT-II blood level: People judge color, nausea, and sexual sides — not a plasma concentration. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Nausea / vomiting: Signature acute and dose-limiting side in clinical sexual-function and pilot work; community rates it as very common on first doses and during load. trialforum
- Flushing cluster: Facial flush, warmth, yawning, and stretching complex within hours of a shot — often treated as “it hit” signals in logs and correlated with erection onset in clinical notes. trialforum
- Appetite drop: Sought for cut phases or unwanted low intake; monitor unintended under-eating. forum
- Headache / dizziness: Commonly listed among acute sides in consumer health and regulator summaries. forumtrial
- GI extras: Vomiting, abdominal cramps, and diarrhea appear in consumer/clinical side lists beyond simple nausea. forum
- Acne (reported): Listed among milder risks in clinician-facing overviews of recreational use. forum
- Nails / uneven pigment: Consumer summaries include dark nail lines and uneven darkening as possible cosmetic harms. forum
- BP / autonomic / CV notes: Hypertension, chest pain, breathing-issue language appear in safety reviews and public-health warning copy; caution discourse for cardiovascular risk. forumtrial
- Injection-site infection / abscess: Unsterile technique, multi-dose vial contamination, and abscesses appear in clinician social-media warnings about viral “Barbie drug” use. forum
- Nasal-specific: Nasal irritation, unpredictable absorption, and identity/purity unknowns beyond injectable vial debates. forum
- Source, legality, impurities: Unlicensed sales, mislabeling, underfilled vials, nasal multi-unknown ingredients, and multi-country bans/warnings — gray-market identity and sterile quality are core risks. trialforum
- Nausea is still the limiter (2025–26): r/Melanotan2 dose-threshold threads still land on mild nausea around ~100 mcg for many, worse at 200–250+ mcg daily, with a loud minority who get none. Bedtime + start-low is the copied fix, not ‘push through a 1 mg load.’ forum
- 2025–26 stop reasons: Face too dark, moles/freckles going black, load nausea, or sexual sides that will not quit — then a PT-141 thread, not a higher-mg load. forum
- Fatigue / somnolence: Higher research doses (e.g., ~0.03 mg/kg class in Dorr escalation) produced sleepiness/fatigue. trial
- Sexual / priapism risk: Spontaneous erections are documented; rare prolonged painful erection (priapism) is a medical emergency with published case reports (including multi-hour events after recreational use). trial
- Moles / freckles / naevi: Darkening, enlargement, eruptive new moles/freckles, and rapid lesion change are among the most serious dermatologic concerns in case series; changing lesions need professional evaluation. trial
- Melanoma discourse: Case reports of melanoma or atypical lesions around MT-II use exist; reviews and experts note heavy UV confounds and incomplete causal proof — agencies and Skin Cancer Foundation still warn and discourage use. trial
- Oral mucosa / gums: Pigment changes of oral mucosa / attached gingiva reported with injectable use in case literature (including cumulative multi-mg exposure contexts). trial
- TGA-class serious mentions: Australian warnings have listed increased moles/freckles plus reports of kidney dysfunction and brain swelling (cerebral oedema language) in melanotan-II risk summaries. trial
- Systemic toxicity / rhabdomyolysis (extreme dose): Case report after ~6 mg SC internet Melanotan II with systemic toxicity and rhabdomyolysis — underscores gray-market dose error risk. trial
- UV still dangerous: Darker color does not authorize unprotected burning; UV remains a melanoma risk factor independent of peptide. trial
- Detection / mole screening problem: Rapid mole darkening can make clinical skin-cancer detection harder even when causation is debated. trial
- Not approved for cosmetic tanning: No jurisdiction treats gray-market MT-II as a cleared consumer tanning drug; research-chemical labeling does not equal safety testing. trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.